As med tech companies roll out innovative radiation devices to treat breast cancer, medical experts are debating the pros and cons of a new technique that could be less expensive and more convenient than traditional therapy for the disease.
Scientists at Nottingham Trent University, Nottingham University Hospitals NHS Trust and the University of Nottingham have identified a possible target for triple negative breast cancers, offering vaccine makers a potential path forward against the cancer and patients hope where other treatments have failed.
A new biomarker for lethal cases of basal-like breast cancer (BLBC) could provide a new and more precise target for cancer drug developers. Researchers at Boston University say they found that a molecule named IL13RA2 (IL13R alpha2) is found clustered on the surface of BLBC cells among late-stage and metastatic cases, when the disease is almost impossible to slow down.
As physicians turn to mammography as a more reliable way to diagnose breast cancer, a new study shows that the screening method does not reduce the number of deaths from the disease and could lead to overdiagnosis, suggesting a few kinks in the system.
Dalantercept (ACE-041) is owned by Acceleron and is currently in early clinical trials for liver and kidney carcinomas. More recently, though, researchers at Lund University demonstrated that it could block the activin receptor-like 1 (ALK1) pathway, suggesting it may also slow metastasis in aggressive breast cancer.
Scientists from Cincinnati Children's Hospital Medical Center report that the best way to prevent breast cancer from growing resistant to therapies may be to genetically strip cancer cells' natural defenses against intrinsic stress.
Just as the latest breast tomosynthesis equipment option has made it through the FDA with an approval for Siemens, startup VuComp has submitted its own PMA to gain approval for its computer-aided detection software for digital breast tomosynthesis images.
Investigators believe that they have found a new approach to treating HER2-positive breast cancer in a class of enzymes called protein tyrosine phosphatases, or PTPs, which plays a role in cell proliferation.
According to a new report, the U.S. wastes as much as $4 billion a year in unnecessary medical costs that are the result of mammograms that produce false positives, and treatments of certain breast tumors that aren't life-threatening.
About two months ago, Nektar was talking up a big expansion, making way for the new staffers that would be needed to start commercializing the breast cancer drug NKTR-102. Today, the biotech may be rethinking that plan, as the drug failed in a pivotal late-stage study.